Vascular Biogenics — Notable Labs — Investor Presentation (May 2024)
27 slides from Vascular Biogenics's investor presentation, May 30, 2024
Slide 1: Propelling the Right Drugs to the Right Patients
Propelling the Right Drugs to the Right Patients
Slide 2: Disclaimer
Disclaimer Forward Looking Statements: This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding Notable Labs, Ltd’s (“Notabl
Slide 3: Notable: Predictive Medicine Platform to Derisk & Propel Clinical Stage Assets
Notable: Predictive Medicine Platform to Derisk & Propel Clinical Stage Assets rapeutics company with a to drug development Lead Program: Volasertib Predictive Medicine Platform (PMP) * Originally developed by Boehringer Ingelheim through Phase 3; * Measures functional cell response to treatment ona
Slide 4: We Aim to Deliver Better and More Predictable Outcomes for Patients
We Aim to Deliver Better and More Predictable Outcomes for Patients Precision Medicine (one-dimensional) * Targets genomic mutations * Only 15% cancer patients carry actionable mutations * Response rate often low (considers only genetic mutations) Complete Response Rate (composite) _E_Hs = pact tore
Slide 5: Notable PMP Leverages & Further De-risks BI's Enhanced, FDA-Supported Program
Notable PMP Leverages & Further De-risks Bl’s Enhanced, FDA-Supported Program? Statistically significant clinical response and survival advantage Difference not statistically significant FOA Breakthrough Designation Discovery Phase2 Pre-Clinical Phase3, Fixed Dosing Fixed Dosing Boehringer Ingelheim
Slide 6: Predictive Medicine Platform
* Notable Predictive Medicine Platform
Slide 7: Genomics-Based Precision Medicines are Limited
Genomics-Based Precision Medicines are Limited * Notable tic Mutatio: Less than 15% of cancer patients? carry a known actionable genetic marker, and thus can benefit from traditional precision medicines In many clinical settings, genomics-based precision medicines deliver moderate or low clinical re
Slide 8: Predictive Medicine Platform Merges Biology Advanced Technology
Predictive Medicine Platform Merges Biology Advanced Technology a Fresh Patient Sample Multiple Readouts Includes Cancerand Immune Cells Biosimulation Assay at the Single Cell Level Patient Response Prediction live Microenvironment Parameters A * O Dying (Apo Media Components Cjtokines/GromthFactors
Slide 9: All Platform-Predicted Responders Clinically Responded to Their Actual Treatment
All Platform-Predicted Responders Clinically Responded to Their Actual Treatm: Clinical Validation Trial with Stanford in MDS?: Results of the 21 Patients Treated with Platform-Screened Compounds? Predicted Response Actual Clinical Response from Patient Samples to Patients’ Treatment 3 Js Predicted
Slide 10: 97% Predicted Responders Achieved Clinical Response Across Validation Trials
97% Predicted Responders Achieved Clinical Response Across 4 Validation Trials @ Clinical Non-Responder @ Clinical Responder Predicted Responders, 83%" (n-9) 100%" (v=10) 100%" (n=18) 100%" (v=13) 1 7 je 7 . , > / i LZ eo o o - Se o + p : 3 3 . ° . 2 4 * a H F ‘ = eee Vv 4 e Vv v ‘Stanford Universit
Slide 11: Volasertib: Strong Predictive PMP Performance Further De-Risks Program
Volasertib: Strong Predictive PMP Performance Further De-Risks Program Least sensitive 10 08 g © DeNow AML 3 0.6 o @ R/RAML a g 04 © tiot speciied 2 Highly Volasertib- sensitive (n=19 of 41) Most sensitive Highly sensitive samples included 50% of R/R AML patients Presented at AACR 2024, San Diego, C
Slide 12: Volasertib Lead Candidate
* Notable Volasertib Lead Candidate
Slide 13: Acute Myeloid Leukemia (AML) is an Urgent Unmet Need
Acute Myeloid Leukemia (AML) is an Urgent Unmet Need Esi Acute Myeloid Leukemia (AML) timated in 2024 (US): 20,800 cases; 11,220 deaths? Not Eligible for Intensive Chemotherapy (>50% of AML°) 1. American Ca toss statistes.ntmi, accessed 4/2 ‘e-myeloid oukemia/about/key: ty website, glcancerfypes/acu
Slide 14: Volasertib: PLK1 Plays Central Role in Leukemia and Other Cancers
Volasertib: PLK1 Plays Central Role in Leukemia and Other Cancers * Polo-like kinase 1 (PLK1) plays central role in cancer cell proliferation PLK1 over-expression has been edondneckauomourclerchems 652659 found in multiple cancers and associated with poor prognoses * PLK1 inhibition leads to death =
Slide 15: Boehringer Ingelheim Volasertib Front Line AML Clinical Summary
Boehringer Ingelheim Volasertib Front Line AML Clinical Summary 735 AML Patients Across Phase 2 and Phase 3 Trials Treatment!: LDAC + Fixed/Flat Dose Volasertib Vs. LDAC + Placebo Phase 2 (US/Western Europe)? Phase 3 (Worldwide)* * Volasertib arm * Volasertib arm + CR+ Cri: 31%; durable remissions,
Slide 16: Volasertib Phase 2 and Phase 3 Trial Results Summary
Volasertib Phase 2 and Phase 3 Trial Results Summary Summary of AML Results = | a | [me] cre | alae” 4s Treatment a 22 48a Complete Response (CR) 6.7% (3) 14.3% (6) 12.2% (27) 15.1% (67) cri 6.7%(3) 16.7%(7) 5.0% (21) 12.6% (56) Overall Response Rate (CR + ri) 13.3% (6) 31.0% (13) 17.1% (38) 27.7% (
Slide 17: Febrile Neutropenia is a Common and Manageable On-Target Event in R/R AML
Febrile Neutropenia is a Common and Manageable On-Target’ Event in R/R AML 100 Percent of Patients with Febrile Neutropenia 90 30 1S) 70 60 50 oo) oa 7 7 40 ! = | | 54 ce 57 - ia 47 | 47 az | 10 | ; | | | | >t | — L _ «Cl Venetoclax (1) IDAC (2) IDAC (3) Comp (4) BI Ph2 (5) BI Ph3 (6) MEC (7) Ida-FL
Slide 18: BI Phase 3 Post Hoc Analysis Triggered Enhanced BI Trial at MDACC
BI Phase 3 Post Hoc Analysis Triggered Enhanced BI Trial at MDACC Discovery Pre-Clinical Phase 3 Post Hoc Analysis * Clinical responses across all risk groups, including high risk (complex genetics; p17/TP53) * — Inconsistent antibiotic prophylaxis: febrile neutropenia, infections, including grade 5
Slide 19: Notable's Phase 2 Trial Overview
* Notable Notable’s Phase 2 Trial Overview
Slide 20: Notable's Phase 2 Further Enhanced By PMP Patient Selection
Notable’s Phase 2 Further Enhanced By PMP Patient Selection Part 1 Part 2 Antibiotics Antibiotics Key Inclusion Criteri . . *tonfemed AML BSA-Dosing BSA-Dosing * Ineligible for intensive chemo * 1-3 failed treatments Selection by PMP-Platform Enroll the Most Volaser ve Patients Goal Part 1: Goal Par
Slide 21: Volasertib Phase 2 Trial: Anticipated Near-Term Milestones
Volasertib Phase 2 Trial: Anticipated Near-Term Milestones FDA Submission Lead-In Data Continuous Data Read-Out Predictive Selection Starts First Site Initiated FDA post lead-in meeting 1 —- Day 30 post submission a Notable n
Slide 22: Corporate Summary and Intellectual Property
* Notable Corporate Summary and Intellectual Property
Slide 23: Notable Business Model is Scalable
Notable Business Model is Scalable Predict Clinical Responders Through the Notable Platform. Propel Advanced-Stage Drugs over Finish Line kx ¢©¢€©§€=<—hlhvwwUE Buiies Mose Biology and Technology Identifies patients most likely to respond to a treatment (no need for genetic markers, e.g. next generat
Slide 24: Intellectual Property Built on Three Pillars
Intellectual Property Built on Three Pillars * In-licensed BI portfolio Protected via trade secrets © 23 issued patents across API, formulation, method of use, Parsing of knowledge across scientific, engineering and data teams method of manufacture Drug-specific method filings protect as above © API
Slide 25: Cash Position and Stock Information
Cash Position and Stock Information * NASDAQ: NTBL (launched on Oct 17, 2023, following reverse merger with VBLT) * Office and laboratories in Foster City, California ¢ $8.2 mm cash and cash equivalents (March 31, 2024) o $6.8 mm cash and cash equivalents (May 9, 2024) * 9.7mm shares outstanding o N
Slide 26: Experienced Leaders From Across Therapeutics, Diagnostics & Technology
Experienced Leaders From Across Therapeutics, Diagnostics & Technology 932028 Thomas Bock, M.D., MBA Chief Executive Officer Chief Executive Officer | HeritX SVP and Global Medical Head | Alexion VP and Global Medical Head | Celgene a Notable Joseph Wagner, Ph.D. Chief Scientific Officer President a
Slide 27: Board of Directors: Leaders from Premier Life Science Companies
Board of Directors: Leaders from Premier Life Science Companies VVIAIoO@Ves Tuomo Patsi Thomas Graney Thomas Dubin Chair Chair Audit Committee Chair Compensation Committee EVP, Commercial Chief Executive Officer Seagen Oxurion Vice Chair i a Norwalk Hospital President International Chief Financial O